Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes virus-thymedine kinase for glioma tumor vaccine therapy

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 486-494

  Okada, Hideho ^a,b,c   Attanucci, Jason ^a,b   Tahara, Hideaki ^a   Pollack, Ian F ^a,b   Bozik, Michael E ^a,b   Chambers, William H ^a,b   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Kauffman's Building ^*  (United States)

Author keywords

Brain tumors; Herpes simplex virus thymidine kinase; Interleukin 4; Retroviral vectors; Tumor vaccine

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; CYTOKINE; GANCICLOVIR; INTERLEUKIN 4; THYMIDINE KINASE; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; FIBROBLAST; GLIOBLASTOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RETROVIRUS; TUMOR CELL;

ANIMALIA; DNA VIRUSES; ENCEPHALOMYOCARDITIS VIRUS; HERPES; HERPESVIRIDAE; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0034074653     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700140     Document Type: Article

References (46)

1. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. J Neurosurg. 1989;71:487-493.
2. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol. 1989;7:1701-1709.
3. Sawamura Y, Hosokawa M, Kuppner MC, et al. Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res. 1989;49:1843-1849.
4. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA. 1996;93:10399-10404.
5. Wakimoto H, Abe J, Tsunoda R, et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 1996;56:1828-1833.
6. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA. 1996;93:2909-2914.
7. Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine. Gene Ther. 1999;6:219-226.
8. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57: 503-512.
9. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol. 1994;153:5659-5673.
10. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
11. Bozik ME, Chambers WH, Lotze MT, et al. T-cell-dependent intracerebral tumor regression of a 9L gliosarcoma expressing mIL-4 in a syngeneic host. Proc Annu Meet Am Assoc Cancer Res. 1996;36:A2800. Abstract.
12. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med. 1995;1:1297-1302.
13. + progenitor cells. Exp Hematol. 1998;26:63-72.
14. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of cancer patients. Ann Surg. 1997;226:1-5.
15. Morse MA, Zhou LJ, Tedder TF, et al. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann Surg. 1997;226:6-16.
16. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
17. Stoppacciaro A, Paglia P, Lombardi L, et al. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol. 1997;27:2375-2382.
18. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
19. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol. 1991;11:5848.
20. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retrovirus vectors expressing biologically active human inteleukin-12. Hum Gene Ther. 1994;5: 1493-1506.
21. Okada H, Miyamura K, Itoh T, et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther. 1996;3:957-964.
22. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
23. Culver KW, Ram Z, Walbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
24. Ram Z, Culver KW, Walbridge S, et al. In situ retroviral gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
25. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354-1361.
26. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
27. Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998;4:581-587.
28. Elder EM, Lotze MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther. 1996;7:479-487.
29. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
30. Bahnson AB, Dunigan JT, Baysal BE, et al. Centrifugal enhancement of retroviral-mediated gene transfer. J Virol Methods. 1995;54:131-143.
31. Benedetti S, Bruzzone MG, Polio B, et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res. 1999;59:645-652.
32. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors only occurs in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10: 4239-4242.
33. Gooch JL, Lee A, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 1998;58:4199-4205.
34. Fakhrai H, Shawler DL, Van BC, et al. Construction and characterization of retroviral vectors for interleukin-2 gene therapy. J Immunother. 1997;20:437-448.
35. Wakimoto H, Yoshida Y, Aoyagi M, et al. Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human glioma cells for tumor vaccination therapy. Jpn J Cancer Res. 1997;88:296-305.
36. Pippin BA, Rosenstein M, Jacob WF, et al. Local interleukin-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with interleukin-2. Cancer Gene Ther. 1994; 1:35-42.
37. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol. 1995;155:1393-1403.
38. Suminami Y, Elder EM, Lotze MT, et al. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother. 1995; 17:238-248.
39. Tahara H, Lotze MT, Robbins PD, et al. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 1995; 6:1607-1624.
40. Kalman B, Lublin FD. Immunopathogenic mechanisms in experimental allergic encephalomyelitis. Curr Opin Neurol Neurosurg. 1993;6:182-188.
41. Schmidt S, Linington C, Zipp F, et al. Multiple sclerosis: comparison of the human T-cell response to S100β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain. 1997;120:1445.
42. Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg. 1981;55:32-42.
43. Sobol RE, Fakhrai H, Shawler D, et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995;2: 164-167.
44. Trouillas P. Immunologie et immunotherapie des tumeurs cerebrales. Etat actuel. Rev Neurol. 1973;128:23-38.
45. Bloom HJG, Peckham MJ, Richardson AE, et al. Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer. 1973;27: 253-267.
46. Mahaley MS Jr, Bigner DD, Dudka LF, et al. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg. 1983;59:201-207.